Zeitschrift für entzündliche Darmerkrankungen und -störungen

Role/Risks of Proton Pump Inhibitors and Infliximab in IBD Patients

Abstract

Lim Vuanghao

Proton Pump Inhibitors (PPIs) are the most generally endorsed class of medicine for the treatment of indigestion and corrosive related issues. They work by obstructing the site of corrosive creation in the parietal cell of the stomach. Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases mainly Ulcerative Colitis (UC) and Crohn's Disease (CD). Infliximab targets TNF, thought to be more related to Th1 cytokines.